OLD Second National Bank of Aurora Buys 81 Shares of Zoetis Inc. (NYSE:ZTS)

OLD Second National Bank of Aurora increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 0.7% in the third quarter, HoldingsChannel reports. The firm owned 11,684 shares of the company’s stock after purchasing an additional 81 shares during the period. OLD Second National Bank of Aurora’s holdings in Zoetis were worth $2,283,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. First Personal Financial Services acquired a new position in shares of Zoetis in the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis during the 3rd quarter worth about $33,000. Quarry LP grew its holdings in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the last quarter. LRI Investments LLC acquired a new stake in Zoetis in the 1st quarter valued at about $43,000. Finally, Fortitude Family Office LLC raised its stake in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after acquiring an additional 222 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ZTS. BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Stifel Nicolaus boosted their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Piper Sandler boosted their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Stock Performance

NYSE ZTS opened at $173.95 on Wednesday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock has a market cap of $78.48 billion, a PE ratio of 32.70, a PEG ratio of 2.70 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The firm’s fifty day moving average price is $187.81 and its two-hundred day moving average price is $180.04.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the previous year, the firm posted $1.36 earnings per share. Zoetis’s revenue for the quarter was up 11.6% on a year-over-year basis. On average, equities analysts expect that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.99%. Zoetis’s payout ratio is currently 32.52%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.